Orexo sells its peptide technology

20-Jun-2005

Orexo AB has sold the rights for its cell-penetrating Peptide technology, CPP. "Orexo's strategy is to regularly evaluate and analyze both its products and technologies," says Zsolt Lavotha, President and CEO of Orexo AB. "Today, we have a portfolio of several product candidates at different stages of development, all of which are based on our internally developed and patented technology platforms. Our business model is based on short development times and low development risk. Our assessment is that, while promising, Orexo's cell-penetrating peptide technology (CPP) is in an early research phase. Accordingly, the sale of this technology is a natural step for Orexo at this time," concludes Zsolt Lavotha.

Purchase price was 9,5 MSEK. The joint purchasers are professor Ülo Langel and Dr. Mattias Hällbrink through company.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances